Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $16.50.

A number of brokerages recently issued reports on OCUL. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th.

Ocular Therapeutix Price Performance

NASDAQ OCUL traded up $0.11 on Friday, reaching $7.65. The company's stock had a trading volume of 1,467,233 shares, compared to its average volume of 1,552,331. The firm has a market cap of $1.22 billion, a PE ratio of -5.80 and a beta of 1.34. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix has a 52 week low of $4.06 and a 52 week high of $11.78. The business has a 50-day moving average price of $7.74 and a 200 day moving average price of $8.86.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The company had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. Sell-side analysts expect that Ocular Therapeutix will post -0.98 EPS for the current year.

Remove Ads

Insider Activity at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,475 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares in the company, valued at $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Donald Notman sold 11,119 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the transaction, the insider now directly owns 193,444 shares in the company, valued at approximately $1,510,797.64. The trade was a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,895 shares of company stock valued at $283,772 over the last quarter. Corporate insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Ocular Therapeutix in the 4th quarter valued at about $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Ocular Therapeutix by 48.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 218,588 shares of the biopharmaceutical company's stock worth $1,867,000 after purchasing an additional 70,904 shares in the last quarter. Two Sigma Advisers LP grew its holdings in shares of Ocular Therapeutix by 252.9% in the 4th quarter. Two Sigma Advisers LP now owns 36,700 shares of the biopharmaceutical company's stock valued at $313,000 after buying an additional 26,300 shares during the period. Two Sigma Investments LP increased its position in shares of Ocular Therapeutix by 21.9% in the 4th quarter. Two Sigma Investments LP now owns 252,939 shares of the biopharmaceutical company's stock valued at $2,160,000 after buying an additional 45,518 shares in the last quarter. Finally, Second Line Capital LLC raised its stake in Ocular Therapeutix by 29.4% during the 4th quarter. Second Line Capital LLC now owns 340,098 shares of the biopharmaceutical company's stock worth $2,904,000 after buying an additional 77,288 shares during the period. 59.21% of the stock is currently owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.